A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...
This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...
Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...
1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...
The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...
